Top-News
ImmunoVaccine Inc.
Beiträge:
3
Zugriffe: 2.269 / Heute: 1
Zugriffe: 2.269 / Heute: 1
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR S&P U.S. Utilities Select Sector UCITS ETF
Perf. 12M: +19,02%
SPDR MSCI Europe Financials UCITS ETF
Perf. 12M: +18,71%
SPDR MSCI Europe Communication Services UCITS ETF
Perf. 12M: +18,08%
SPDR MSCI Europe Utilities UCITS ETF
Perf. 12M: +17,94%
SPDR MSCI World Utilities UCITS ETF
Perf. 12M: +16,30%
(0 Bewertungen)
Marketwired·Mehr Nachrichten von Marketwired
Immunovaccine Study Demonstrates Early Protection Against Anthrax with Single Dose Experimental Vaccines / Proprietary DepoVax Technology Works with Multiple rPA Antigens
HALIFAX, NOVA SCOTIA -- (Marketwired) -- 01/28/15 -- Immunovaccine Inc. ("Immunovaccine") (TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that three different recombinant protective antigen (rPA) vaccines formulated with its novel DepoVax™ enhancement technology protected animals against a lethal anthrax challenge after a single vaccination. The National Institutes of Health (NIH) led study demonstrates the potential of DepoVax as a universal enabler of single dose rPA-based anthrax vaccines.
The anthrax challenge study was designed to evaluate the early protection potential of single dose DepoVax/rPA vaccines. A very low dose of rPA that is known to provide partial protection in the rabbit model was used. This allowed a comparison of the potency of the various rPA vaccines formulated in DepoVax.
Rabbits were exposed to a lethal dose of the anthrax causing bacterial spores (B. anthracis) 28 days following a single vaccination. The DepoVax/rPA vaccines provided good protection to animals against anthrax with a single dose, protecting a total of 15 of 24 animals across the three different rPA sources. As expected, control animals injected with a saline solution all succumbed to the anthrax challenge. Animals given a placebo DepoVax vaccine with no antigen also succumbed to anthrax, demonstrating that protection is mediated by the combination of DepoVax and rPA.
Marketwired·Mehr Nachrichten von Marketwired
Immunovaccine Study Demonstrates Early Protection Against Anthrax with Single Dose Experimental Vaccines / Proprietary DepoVax Technology Works with Multiple rPA Antigens
HALIFAX, NOVA SCOTIA -- (Marketwired) -- 01/28/15 -- Immunovaccine Inc. ("Immunovaccine") (TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that three different recombinant protective antigen (rPA) vaccines formulated with its novel DepoVax™ enhancement technology protected animals against a lethal anthrax challenge after a single vaccination. The National Institutes of Health (NIH) led study demonstrates the potential of DepoVax as a universal enabler of single dose rPA-based anthrax vaccines.
The anthrax challenge study was designed to evaluate the early protection potential of single dose DepoVax/rPA vaccines. A very low dose of rPA that is known to provide partial protection in the rabbit model was used. This allowed a comparison of the potency of the various rPA vaccines formulated in DepoVax.
Rabbits were exposed to a lethal dose of the anthrax causing bacterial spores (B. anthracis) 28 days following a single vaccination. The DepoVax/rPA vaccines provided good protection to animals against anthrax with a single dose, protecting a total of 15 of 24 animals across the three different rPA sources. As expected, control animals injected with a saline solution all succumbed to the anthrax challenge. Animals given a placebo DepoVax vaccine with no antigen also succumbed to anthrax, demonstrating that protection is mediated by the combination of DepoVax and rPA.
Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »
Es gibt keine neuen Beiträge.
Ich:
